zintellect
climb higher

Opportunity Title: FDA Fellowship in High Throughput Assessment of Opioid Drugs by Automated Dissolution Testing
Opportunity Reference Code: FDA-CDER-2024-1397

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2024-1397

How to Apply ***Connect with ORISE...on the GO!*** Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 6/28/2024 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**

CDER Office/Lab and Location: A research opportunity is available in the Office of Testing and Research (OTR), Office of Pharmaceutical Quality (OPQ), Food and Drug Administration (FDA) located in St. Louis, Missouri. This is a collaborative research project in the Center for Drug Evaluation and Research (CDER). CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the FDA, CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This research covers more than just medicines.

Research Project: This project will involve the development and validation of methods for high-throughput characterization and quantification of opioid drug products. The project will involve development of sample preparation procedures utilizing an automated dissolution testing system, characterization of the performance of the preparation methods, and validation. The prepared samples will be tested for drug release performance.

Learning Objectives: Under the guidance of the mentor, the participant will gain experience with advanced pharmaceutical analysis involving liquid chromatographic techniques and dissolution testing. The participant will also be able to enhance their communication skills through preparation of manuscripts, oral presentations, and posters.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

Opportunity Title: FDA Fellowship in High Throughput Assessment of Opioid Drugs by Automated Dissolution Testing
Opportunity Reference Code: FDA-CDER-2024-1397

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the St. Louis, Missouri, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received a master's or doctoral degree in one of the relevant fields. Degree must have been received within the past five years. Prior experience with liquid chromatographic techniques and dissolution testing is preferred. Familiarity with analytical method development is also highly desirable.

Eligibility

- **Degree:** Master's Degree or Doctoral Degree received within the last 60

Opportunity Title: FDA Fellowship in High Throughput Assessment of Opioid Drugs by Automated Dissolution Testing
Opportunity Reference Code: FDA-CDER-2024-1397

Requirements

month(s).

- **Discipline(s):**
  - **Chemistry and Materials Sciences** (1 👁)
  - **Engineering** (1 👁)
  - **Life Health and Medical Sciences** (1 👁)

Affirmation

I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)

I have read the FDA Ethics Requirements.